A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2012-10-02

AUTHORS

Jill E. Lavigne, Charles Heckler, Jennifer L. Mathews, Oxana Palesh, Jeffrey J. Kirshner, Raymond Lord, Andrew Jacobs, Eric Amos, Gary R. Morrow, Karen Mustian

ABSTRACT

Gabapentin is used for the treatment of hot flashes and neuropathic pain in breast cancer survivors, and is commonly used off-label for the treatment of anxiety. Yet, clinical trial evidence to support the use of gabapentin for anxiety symptoms is lacking. In a randomized, double-blinded controlled trial we compared 300 mg gabapentin versus 900 mg gabapentin versus placebo. Subjects were 420 breast cancer patients who had completed all chemotherapy cycles. Anxiety traits and current (state) anxiety were measured using the Speilberger Strait-Trait Anxiety Inventory at baseline, 4 and 8 weeks. Pain was measured at baseline using a 10-point scale. Analyses included analysis of covariance and ordinary least squares regression. At 4 weeks, state anxiety change scores were significantly better for gabapentin 300 and 900 mg (p = 0.005) compared to placebo. The magnitude of improvement was proportional to baseline state anxiety. At 8 weeks, the anxiolytic effects of gabapentin compared to placebo persisted (p < 0.005). We found no significant interactions. The lower dose (300 mg) was associated with the best treatment outcomes for all patients except those with the highest baseline anxiety. Given its similar pharmacology, efficacy in the treatment of hot flashes, and low cost, gabapentin may provide a low cost and parsimonious alternative treatment choice for breast cancer survivors presenting in primary care practices with anxiety symptoms. Gabapentin is effective for hot flashes, and, therefore, may provide therapeutic benefit for both anxiety and hot flashes at a generic drug price. For patients reluctant to take a controlled substance, such as a benzodiazepine, gabapentin may offer an alternative therapy. Similarly, patients with a history of substance use may benefit from gabapentin without risk of addiction or abuse. For cancer survivors experiencing both hot flashes and anxiety, gabapentin may provide a single effective treatment for both and is an alternative therapy for anxiety for patients unwilling to take a benzodiazepine or those with a history of substance use. More... »

PAGES

479-486

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10549-012-2251-x

DOI

http://dx.doi.org/10.1007/s10549-012-2251-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1050696961

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/23053645


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Amines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Anxiety Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anxiety", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclohexanecarboxylic Acids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gabapentin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survivors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "gamma-Aminobutyric Acid", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Wegmans School of Pharmacy, St. John Fisher College, 3690 East Avenue, 14618, Rochester, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.417560.1", 
          "name": [
            "Wegmans School of Pharmacy, St. John Fisher College, 3690 East Avenue, 14618, Rochester, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lavigne", 
        "givenName": "Jill E.", 
        "id": "sg:person.01062636273.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01062636273.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiation Oncology, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.412750.5", 
          "name": [
            "Department of Radiation Oncology, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Heckler", 
        "givenName": "Charles", 
        "id": "sg:person.01051076462.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01051076462.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Wegmans School of Pharmacy, St. John Fisher College, 3690 East Avenue, 14618, Rochester, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.417560.1", 
          "name": [
            "Wegmans School of Pharmacy, St. John Fisher College, 3690 East Avenue, 14618, Rochester, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mathews", 
        "givenName": "Jennifer L.", 
        "id": "sg:person.0723160650.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723160650.68"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Psychiatry, Stanford University Medical School, Palo Alto, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.168010.e", 
          "name": [
            "Department of Psychiatry, Stanford University Medical School, Palo Alto, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Palesh", 
        "givenName": "Oxana", 
        "id": "sg:person.01165325062.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165325062.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Community Clinical Oncology Base, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.412750.5", 
          "name": [
            "Community Clinical Oncology Base, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kirshner", 
        "givenName": "Jeffrey J.", 
        "id": "sg:person.011556615277.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011556615277.91"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Community Clinical Oncology Base, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.412750.5", 
          "name": [
            "Community Clinical Oncology Base, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lord", 
        "givenName": "Raymond", 
        "id": "sg:person.01031136534.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01031136534.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Community Clinical Oncology Base, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.412750.5", 
          "name": [
            "Community Clinical Oncology Base, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jacobs", 
        "givenName": "Andrew", 
        "id": "sg:person.01361147022.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01361147022.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Wegmans School of Pharmacy, St. John Fisher College, 3690 East Avenue, 14618, Rochester, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.417560.1", 
          "name": [
            "Wegmans School of Pharmacy, St. John Fisher College, 3690 East Avenue, 14618, Rochester, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Amos", 
        "givenName": "Eric", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiation Oncology, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.412750.5", 
          "name": [
            "Department of Radiation Oncology, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Morrow", 
        "givenName": "Gary R.", 
        "id": "sg:person.01322527467.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322527467.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiation Oncology, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.412750.5", 
          "name": [
            "Department of Radiation Oncology, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mustian", 
        "givenName": "Karen", 
        "id": "sg:person.0612440144.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0612440144.77"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/clpt.2011.3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048031705", 
          "https://doi.org/10.1038/clpt.2011.3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00127-009-0068-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021746171", 
          "https://doi.org/10.1007/s00127-009-0068-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00023210-200822010-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014386251", 
          "https://doi.org/10.2165/00023210-200822010-00003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11764-008-0072-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029624366", 
          "https://doi.org/10.1007/s11764-008-0072-z"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-10-02", 
    "datePublishedReg": "2012-10-02", 
    "description": "Gabapentin is used for the treatment of hot flashes and neuropathic pain in breast cancer survivors, and is commonly used off-label for the treatment of anxiety. Yet, clinical trial evidence to support the use of gabapentin for anxiety symptoms is lacking. In a randomized, double-blinded controlled trial we compared 300\u00a0mg gabapentin versus 900\u00a0mg gabapentin versus placebo. Subjects were 420 breast cancer patients who had completed all chemotherapy cycles. Anxiety traits and current (state) anxiety were measured using the Speilberger Strait-Trait Anxiety Inventory at baseline, 4 and 8\u00a0weeks. Pain was measured at baseline using a 10-point scale. Analyses included analysis of covariance and ordinary least squares regression. At 4\u00a0weeks, state anxiety change scores were significantly better for gabapentin 300 and 900\u00a0mg (p\u00a0=\u00a00.005) compared to placebo. The magnitude of improvement was proportional to baseline state anxiety. At 8\u00a0weeks, the anxiolytic effects of gabapentin compared to placebo persisted (p\u00a0<\u00a00.005). We found no significant interactions. The lower dose (300 mg) was associated with the best treatment outcomes for all patients except those with the highest baseline anxiety. Given its similar pharmacology, efficacy in the treatment of hot flashes, and low cost, gabapentin may provide a low cost and parsimonious alternative treatment choice for breast cancer survivors presenting in primary care practices with anxiety symptoms. Gabapentin is effective for hot flashes, and, therefore, may provide therapeutic benefit for both anxiety and hot flashes at a generic drug price. For patients reluctant to take a controlled substance, such as a benzodiazepine, gabapentin may offer an alternative therapy. Similarly, patients with a history of substance use may benefit from gabapentin without risk of addiction or abuse. For cancer survivors experiencing both hot flashes and anxiety, gabapentin may provide a single effective treatment for both and is an alternative therapy for anxiety for patients unwilling to take a benzodiazepine or those with a history of substance use.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10549-012-2251-x", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2622650", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2693488", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1092777", 
        "issn": [
          "0167-6806", 
          "1573-7217"
        ], 
        "name": "Breast Cancer Research and Treatment", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "136"
      }
    ], 
    "keywords": [
      "breast cancer survivors", 
      "hot flashes", 
      "cancer survivors", 
      "gabapentin 300", 
      "alternative therapies", 
      "anxiety symptoms", 
      "double-blinded clinical trial", 
      "use of gabapentin", 
      "clinical trial evidence", 
      "substance use", 
      "breast cancer patients", 
      "single effective treatment", 
      "primary care practices", 
      "high baseline anxiety", 
      "alternative treatment choice", 
      "better treatment outcomes", 
      "treatment of anxiety", 
      "magnitude of improvement", 
      "risk of addiction", 
      "chemotherapy cycles", 
      "neuropathic pain", 
      "trial evidence", 
      "cancer patients", 
      "treatment choice", 
      "clinical trials", 
      "anxiolytic effects", 
      "treatment outcomes", 
      "low dose", 
      "effective treatment", 
      "therapeutic benefit", 
      "gabapentin", 
      "placebo", 
      "analysis of covariance", 
      "similar pharmacology", 
      "patients", 
      "baseline anxiety", 
      "care practices", 
      "anxiety change scores", 
      "change scores", 
      "survivors", 
      "symptoms", 
      "Anxiety Inventory", 
      "current anxiety", 
      "weeks", 
      "pain", 
      "treatment", 
      "therapy", 
      "baseline state anxiety", 
      "benzodiazepines", 
      "anxiety", 
      "baseline", 
      "trials", 
      "state anxiety", 
      "significant interaction", 
      "drug prices", 
      "anxiety traits", 
      "dose", 
      "pharmacology", 
      "efficacy", 
      "outcomes", 
      "scores", 
      "risk", 
      "history", 
      "addiction", 
      "subjects", 
      "use", 
      "abuse", 
      "regression", 
      "ordinary least squares regression", 
      "evidence", 
      "substances", 
      "flashes", 
      "benefits", 
      "effect", 
      "generic drug prices", 
      "analysis", 
      "improvement", 
      "practice", 
      "Inventory", 
      "choice", 
      "scale", 
      "cycle", 
      "covariance", 
      "low cost", 
      "cost", 
      "labels", 
      "interaction", 
      "magnitude", 
      "least squares regression", 
      "squares regression", 
      "traits", 
      "prices", 
      "Speilberger Strait-Trait Anxiety Inventory", 
      "Strait-Trait Anxiety Inventory", 
      "state anxiety change scores", 
      "parsimonious alternative treatment choice"
    ], 
    "name": "A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors", 
    "pagination": "479-486", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1050696961"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10549-012-2251-x"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "23053645"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10549-012-2251-x", 
      "https://app.dimensions.ai/details/publication/pub.1050696961"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:26", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_561.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10549-012-2251-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10549-012-2251-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10549-012-2251-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10549-012-2251-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10549-012-2251-x'


 

This table displays all metadata directly associated to this object as RDF triples.

296 TRIPLES      22 PREDICATES      138 URIs      126 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10549-012-2251-x schema:about N0a5af4fc20ef47629b4197383a967fe7
2 N3443cea60d0a4c569838b3affbaf1162
3 N38d51a3e4ab14128b27bce452191cc96
4 N38eb6ad4aa584755ad7563dc20bbdf96
5 N6a7448743dca49059206a77f38263978
6 N84d0e90977704903914d4a1c371e3ccc
7 N9c9d91b022804dcc868a13a727997f3a
8 N9ede66369c7a4ad4a0d0eb1e29862307
9 Na37b3a84b367460887b27f23130b7e92
10 Nc9451a095bf64338b25a2d58ea5314e0
11 Ne1adcfdd220d4dc89c707a1532cbb94d
12 Nff316fc509244eaca105a9018a65582c
13 anzsrc-for:11
14 anzsrc-for:1112
15 schema:author Na4107eb4131f472da8b9d3f9510f6da0
16 schema:citation sg:pub.10.1007/s00127-009-0068-7
17 sg:pub.10.1007/s11764-008-0072-z
18 sg:pub.10.1038/clpt.2011.3
19 sg:pub.10.2165/00023210-200822010-00003
20 schema:datePublished 2012-10-02
21 schema:datePublishedReg 2012-10-02
22 schema:description Gabapentin is used for the treatment of hot flashes and neuropathic pain in breast cancer survivors, and is commonly used off-label for the treatment of anxiety. Yet, clinical trial evidence to support the use of gabapentin for anxiety symptoms is lacking. In a randomized, double-blinded controlled trial we compared 300 mg gabapentin versus 900 mg gabapentin versus placebo. Subjects were 420 breast cancer patients who had completed all chemotherapy cycles. Anxiety traits and current (state) anxiety were measured using the Speilberger Strait-Trait Anxiety Inventory at baseline, 4 and 8 weeks. Pain was measured at baseline using a 10-point scale. Analyses included analysis of covariance and ordinary least squares regression. At 4 weeks, state anxiety change scores were significantly better for gabapentin 300 and 900 mg (p = 0.005) compared to placebo. The magnitude of improvement was proportional to baseline state anxiety. At 8 weeks, the anxiolytic effects of gabapentin compared to placebo persisted (p < 0.005). We found no significant interactions. The lower dose (300 mg) was associated with the best treatment outcomes for all patients except those with the highest baseline anxiety. Given its similar pharmacology, efficacy in the treatment of hot flashes, and low cost, gabapentin may provide a low cost and parsimonious alternative treatment choice for breast cancer survivors presenting in primary care practices with anxiety symptoms. Gabapentin is effective for hot flashes, and, therefore, may provide therapeutic benefit for both anxiety and hot flashes at a generic drug price. For patients reluctant to take a controlled substance, such as a benzodiazepine, gabapentin may offer an alternative therapy. Similarly, patients with a history of substance use may benefit from gabapentin without risk of addiction or abuse. For cancer survivors experiencing both hot flashes and anxiety, gabapentin may provide a single effective treatment for both and is an alternative therapy for anxiety for patients unwilling to take a benzodiazepine or those with a history of substance use.
23 schema:genre article
24 schema:inLanguage en
25 schema:isAccessibleForFree true
26 schema:isPartOf N2c15aa514a4645cb85838f00d9362fb9
27 N84b49dbe1faa4d0eaaeeb72d13d53bac
28 sg:journal.1092777
29 schema:keywords Anxiety Inventory
30 Inventory
31 Speilberger Strait-Trait Anxiety Inventory
32 Strait-Trait Anxiety Inventory
33 abuse
34 addiction
35 alternative therapies
36 alternative treatment choice
37 analysis
38 analysis of covariance
39 anxiety
40 anxiety change scores
41 anxiety symptoms
42 anxiety traits
43 anxiolytic effects
44 baseline
45 baseline anxiety
46 baseline state anxiety
47 benefits
48 benzodiazepines
49 better treatment outcomes
50 breast cancer patients
51 breast cancer survivors
52 cancer patients
53 cancer survivors
54 care practices
55 change scores
56 chemotherapy cycles
57 choice
58 clinical trial evidence
59 clinical trials
60 cost
61 covariance
62 current anxiety
63 cycle
64 dose
65 double-blinded clinical trial
66 drug prices
67 effect
68 effective treatment
69 efficacy
70 evidence
71 flashes
72 gabapentin
73 gabapentin 300
74 generic drug prices
75 high baseline anxiety
76 history
77 hot flashes
78 improvement
79 interaction
80 labels
81 least squares regression
82 low cost
83 low dose
84 magnitude
85 magnitude of improvement
86 neuropathic pain
87 ordinary least squares regression
88 outcomes
89 pain
90 parsimonious alternative treatment choice
91 patients
92 pharmacology
93 placebo
94 practice
95 prices
96 primary care practices
97 regression
98 risk
99 risk of addiction
100 scale
101 scores
102 significant interaction
103 similar pharmacology
104 single effective treatment
105 squares regression
106 state anxiety
107 state anxiety change scores
108 subjects
109 substance use
110 substances
111 survivors
112 symptoms
113 therapeutic benefit
114 therapy
115 traits
116 treatment
117 treatment choice
118 treatment of anxiety
119 treatment outcomes
120 trial evidence
121 trials
122 use
123 use of gabapentin
124 weeks
125 schema:name A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors
126 schema:pagination 479-486
127 schema:productId N0b6ffb8a80064ba199e8c415596677e3
128 N96f70e4ab74446348e309ef4a25100fb
129 Nbe9c32e5a1aa4aa19d3f986966f7d7bd
130 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050696961
131 https://doi.org/10.1007/s10549-012-2251-x
132 schema:sdDatePublished 2022-01-01T18:26
133 schema:sdLicense https://scigraph.springernature.com/explorer/license/
134 schema:sdPublisher N1dd344b481b8457da138a9fba7ff4648
135 schema:url https://doi.org/10.1007/s10549-012-2251-x
136 sgo:license sg:explorer/license/
137 sgo:sdDataset articles
138 rdf:type schema:ScholarlyArticle
139 N0a5af4fc20ef47629b4197383a967fe7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Humans
141 rdf:type schema:DefinedTerm
142 N0b6ffb8a80064ba199e8c415596677e3 schema:name doi
143 schema:value 10.1007/s10549-012-2251-x
144 rdf:type schema:PropertyValue
145 N1dd344b481b8457da138a9fba7ff4648 schema:name Springer Nature - SN SciGraph project
146 rdf:type schema:Organization
147 N2c15aa514a4645cb85838f00d9362fb9 schema:volumeNumber 136
148 rdf:type schema:PublicationVolume
149 N3443cea60d0a4c569838b3affbaf1162 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Female
151 rdf:type schema:DefinedTerm
152 N38d51a3e4ab14128b27bce452191cc96 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Amines
154 rdf:type schema:DefinedTerm
155 N38eb6ad4aa584755ad7563dc20bbdf96 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Anti-Anxiety Agents
157 rdf:type schema:DefinedTerm
158 N486fc519b19b494d8eeca508b6d7b685 rdf:first sg:person.0612440144.77
159 rdf:rest rdf:nil
160 N6a7448743dca49059206a77f38263978 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Cyclohexanecarboxylic Acids
162 rdf:type schema:DefinedTerm
163 N6f12985dccb64a27a1303b7d3f00f2e6 rdf:first sg:person.01031136534.20
164 rdf:rest N809768938af4414585995206e2b28851
165 N809768938af4414585995206e2b28851 rdf:first sg:person.01361147022.29
166 rdf:rest Nc712f2ac33fa4121a4f8795e1119cd37
167 N8347fe046c7c4ff797d9e447c2b9fd72 schema:affiliation grid-institutes:grid.417560.1
168 schema:familyName Amos
169 schema:givenName Eric
170 rdf:type schema:Person
171 N84b49dbe1faa4d0eaaeeb72d13d53bac schema:issueNumber 2
172 rdf:type schema:PublicationIssue
173 N84d0e90977704903914d4a1c371e3ccc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Survivors
175 rdf:type schema:DefinedTerm
176 N96f70e4ab74446348e309ef4a25100fb schema:name pubmed_id
177 schema:value 23053645
178 rdf:type schema:PropertyValue
179 N9c9d91b022804dcc868a13a727997f3a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name gamma-Aminobutyric Acid
181 rdf:type schema:DefinedTerm
182 N9cfd762b455948adb3dcded3fe8baa3c rdf:first sg:person.01165325062.34
183 rdf:rest Na8160950e3e84276a765e3725dec14a0
184 N9ede66369c7a4ad4a0d0eb1e29862307 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Treatment Outcome
186 rdf:type schema:DefinedTerm
187 Na37b3a84b367460887b27f23130b7e92 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Middle Aged
189 rdf:type schema:DefinedTerm
190 Na4107eb4131f472da8b9d3f9510f6da0 rdf:first sg:person.01062636273.82
191 rdf:rest Naadca6ba1aae42539ba46fcc630cab3c
192 Na5de4fc53aab4aff9a6e34b5eb2ce1b4 rdf:first sg:person.0723160650.68
193 rdf:rest N9cfd762b455948adb3dcded3fe8baa3c
194 Na8160950e3e84276a765e3725dec14a0 rdf:first sg:person.011556615277.91
195 rdf:rest N6f12985dccb64a27a1303b7d3f00f2e6
196 Naadca6ba1aae42539ba46fcc630cab3c rdf:first sg:person.01051076462.49
197 rdf:rest Na5de4fc53aab4aff9a6e34b5eb2ce1b4
198 Nbe9c32e5a1aa4aa19d3f986966f7d7bd schema:name dimensions_id
199 schema:value pub.1050696961
200 rdf:type schema:PropertyValue
201 Nc712f2ac33fa4121a4f8795e1119cd37 rdf:first N8347fe046c7c4ff797d9e447c2b9fd72
202 rdf:rest Nf00175da93a1435da5cb5da42e1c232e
203 Nc9451a095bf64338b25a2d58ea5314e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Anxiety
205 rdf:type schema:DefinedTerm
206 Ne1adcfdd220d4dc89c707a1532cbb94d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Breast Neoplasms
208 rdf:type schema:DefinedTerm
209 Nf00175da93a1435da5cb5da42e1c232e rdf:first sg:person.01322527467.95
210 rdf:rest N486fc519b19b494d8eeca508b6d7b685
211 Nff316fc509244eaca105a9018a65582c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
212 schema:name Gabapentin
213 rdf:type schema:DefinedTerm
214 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
215 schema:name Medical and Health Sciences
216 rdf:type schema:DefinedTerm
217 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
218 schema:name Oncology and Carcinogenesis
219 rdf:type schema:DefinedTerm
220 sg:grant.2622650 http://pending.schema.org/fundedItem sg:pub.10.1007/s10549-012-2251-x
221 rdf:type schema:MonetaryGrant
222 sg:grant.2693488 http://pending.schema.org/fundedItem sg:pub.10.1007/s10549-012-2251-x
223 rdf:type schema:MonetaryGrant
224 sg:journal.1092777 schema:issn 0167-6806
225 1573-7217
226 schema:name Breast Cancer Research and Treatment
227 schema:publisher Springer Nature
228 rdf:type schema:Periodical
229 sg:person.01031136534.20 schema:affiliation grid-institutes:grid.412750.5
230 schema:familyName Lord
231 schema:givenName Raymond
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01031136534.20
233 rdf:type schema:Person
234 sg:person.01051076462.49 schema:affiliation grid-institutes:grid.412750.5
235 schema:familyName Heckler
236 schema:givenName Charles
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01051076462.49
238 rdf:type schema:Person
239 sg:person.01062636273.82 schema:affiliation grid-institutes:grid.417560.1
240 schema:familyName Lavigne
241 schema:givenName Jill E.
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01062636273.82
243 rdf:type schema:Person
244 sg:person.011556615277.91 schema:affiliation grid-institutes:grid.412750.5
245 schema:familyName Kirshner
246 schema:givenName Jeffrey J.
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011556615277.91
248 rdf:type schema:Person
249 sg:person.01165325062.34 schema:affiliation grid-institutes:grid.168010.e
250 schema:familyName Palesh
251 schema:givenName Oxana
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165325062.34
253 rdf:type schema:Person
254 sg:person.01322527467.95 schema:affiliation grid-institutes:grid.412750.5
255 schema:familyName Morrow
256 schema:givenName Gary R.
257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322527467.95
258 rdf:type schema:Person
259 sg:person.01361147022.29 schema:affiliation grid-institutes:grid.412750.5
260 schema:familyName Jacobs
261 schema:givenName Andrew
262 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01361147022.29
263 rdf:type schema:Person
264 sg:person.0612440144.77 schema:affiliation grid-institutes:grid.412750.5
265 schema:familyName Mustian
266 schema:givenName Karen
267 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0612440144.77
268 rdf:type schema:Person
269 sg:person.0723160650.68 schema:affiliation grid-institutes:grid.417560.1
270 schema:familyName Mathews
271 schema:givenName Jennifer L.
272 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723160650.68
273 rdf:type schema:Person
274 sg:pub.10.1007/s00127-009-0068-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021746171
275 https://doi.org/10.1007/s00127-009-0068-7
276 rdf:type schema:CreativeWork
277 sg:pub.10.1007/s11764-008-0072-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1029624366
278 https://doi.org/10.1007/s11764-008-0072-z
279 rdf:type schema:CreativeWork
280 sg:pub.10.1038/clpt.2011.3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048031705
281 https://doi.org/10.1038/clpt.2011.3
282 rdf:type schema:CreativeWork
283 sg:pub.10.2165/00023210-200822010-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014386251
284 https://doi.org/10.2165/00023210-200822010-00003
285 rdf:type schema:CreativeWork
286 grid-institutes:grid.168010.e schema:alternateName Department of Psychiatry, Stanford University Medical School, Palo Alto, CA, USA
287 schema:name Department of Psychiatry, Stanford University Medical School, Palo Alto, CA, USA
288 rdf:type schema:Organization
289 grid-institutes:grid.412750.5 schema:alternateName Community Clinical Oncology Base, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA
290 Department of Radiation Oncology, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA
291 schema:name Community Clinical Oncology Base, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA
292 Department of Radiation Oncology, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA
293 rdf:type schema:Organization
294 grid-institutes:grid.417560.1 schema:alternateName Wegmans School of Pharmacy, St. John Fisher College, 3690 East Avenue, 14618, Rochester, NY, USA
295 schema:name Wegmans School of Pharmacy, St. John Fisher College, 3690 East Avenue, 14618, Rochester, NY, USA
296 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...